(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number
WO 03/022863 A1

(51) International Patent Classification⁷: C07H 21/04

(21) International Application Number: PCT/US02/28518

(22) International Filing Date: 9 September 2002 (09.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/317,494 7 September 2001 (07.09.2001) US
60/383,805 30 May 2002 (30.05.2002) US

(71) Applicant (*for all designated States except US*): **THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE** [US/US]; Suite 906, 111 Market Place, Baltimore, MD 21202 (US).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **BUCKHAULTS, Phillip** [US/US]; 3621 Folly Quarter Road, Ellicott City, MD 21042 (US). **KINZLER, Kenneth, W.** [US/US]; 1403 Halkirk Way, Baltimore, MD 21015 (US). **VOGELSTEIN, Bert** [US/US]; 3700 Breton Way, Baltimore, MD 21208 (US).

(74) Agent: **KAGAN, Sarah**; Banner & Witcoff, LTD., 1001 G. Street, N.W., Washington, DC 20001-4597 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/022863 A1

(54) Title: SECRETED AND CELL SURFACE GENES EXPRESSED IN BENIGN AND MALIGNANT COLORECTAL TUMORS

(57) Abstract: Serial analysis of gene expression (SAGE) was used to identify transcripts encoding secreted or cell-surface proteins that were expressed in benign and malignant tumors of the colorectum. A total of 290,394 tags were analyzed from normal, adenomatous and cancerous colonic epithelium. Of the 21,343 different transcripts observed, 957 were found to be differentially expressed between normal and adenoma or between normal and cancer. Forty-nine transcripts were elevated ≥ 20-fold in adenomas, 40 transcripts were elevated ≥ 20-fold in cancers, and nine transcripts were elevated ≥ 20-fold in both. Product of six these nine transcripts (TGFBI, LYS, RDP, MIC-1, REGA, and DEHL) were predicted to be secreted or to reside on the cell surface and these were analyzed in more detail. The abnormal expression levels predicted by SAGE were confirmed by quantitative PCR analyses of each of these six genes. Moreover, the cell types responsible for the elevated expression were identified by in situ hybridization and by PCR analyses of epithelial cells immunoaffinity purified from primary tumors.

SECRETED AND CELL SURFACE GENES EXPRESSED IN BENIGN AND MALIGNANT COLORECTAL TUMORS

BACKGROUND OF THE INVENTION

Technical Field of the Invention

[01] The invention relates to the early detection of colorectal adenoma and carcinoma. In particular it relates to the detection of secreted or cell surface markers in easily collectible bodily samples.

Background of the Art

[02] Colorectal cancer is the second leading cause of cancer death in the United States, with ~130,000 patients diagnosed each year and ~50,000 ultimately succumbing to the disease (1). Most colorectal cancers develop slowly, beginning as small benign colorectal adenomas which progress over several decades to larger and more dysplastic lesions which eventually become malignant. This gradual progression provides multiple opportunities for prevention and intervention. Indeed, benign adenomas can be detected and removed by simple colonoscopy and polypectomy, precluding the need for radical surgical and adjuvant treatments. It is therefore believed that early detection and removal of these benign neoplasms provides the best hope for minimizing morbidity and mortality from colorectal cancer. Various screening methods for detecting early colorectal tumors are available, such as fecal occult blood testing, sigmoidoscopy, and colonoscopy (reviewed in 2). However, none of these methods are optimal, and new approaches are needed.

BRIEF SUMMARY OF THE INVENTION

[03] In a first embodiment a method is provided for detection of colorectal adenoma and carcinoma. An mRNA sample is isolated from feces of a subject. Renal dipeptidase mRNA in said mRNA sample is detected. The amount of renal dipeptidase mRNA in said mRNA sample is compared to amounts of renal dipeptidase mRNA in normal

subjects. An elevated amount of renal dipeptidase mRNA in said mRNA sample is an indicator of colorectal adenoma or carcinoma in the subject.

[04] According to another embodiment of the invention a method is provided for detection of colorectal adenoma or carcinoma. Epithelial cells are isolated from blood of a subject. An mRNA sample is isolated from the epithelial cells. Renal dipeptidase mRNA in said mRNA sample is detected. The amount of renal dipeptidase mRNA in said mRNA sample is compared to amounts of renal dipeptidase mRNA in normal subjects. An elevated amount of renal dipeptidase mRNA in said mRNA sample is an indicator of colorectal adenoma or carcinoma in the subject.

[05] A third embodiment of the invention provides a method for detection of colorectal adenoma or carcinoma. Blood of a subject is contacted with a renal dipeptidase substrate. Activity of renal dipeptidase in said blood is determined by detection of increased reaction product or decreased renal dipeptidase substrate. The amount of activity of renal dipeptidase in blood of the subject is compared to that in normal subjects. An elevated amount of activity of renal dipeptidase in the blood of the subject is an indicator of colorectal adenoma or carcinoma in the subject.

[06] According to another embodiment of the invention a method for detection of colorectal adenoma or carcinoma is provided. Feces of a subject is contacted with a renal dipeptidase substrate. Activity of renal dipeptidase in said feces is determined by detection of increased reaction product or decreased renal dipeptidase substrate. The amount of activity of renal dipeptidase in feces of the subject is compared to that in normal subjects, wherein an elevated amount of activity of renal dipeptidase in the feces of the subject is an indicator of colorectal adenoma or carcinoma in the subject.

[07] Another embodiment of the invention provides a method for detection of colorectal adenoma or carcinoma. An antibody is administered to a subject. The antibody

specifically binds to renal dipeptidase and is labeled with a moiety which is detectable from outside of the subject. The moiety in the subject is detected from outside of the subject. An area of localization of the moiety within the subject but outside the proximal tubules of the kidney identifies colorectal adenoma or carcinoma.

[08] Another method is also provided for detection of colorectal adenoma or carcinoma. An inhibitor of renal dipeptidase is administered to a subject. The inhibitor is labeled with a moiety which is detectable from outside of the subject. The moiety in the subject is detected from outside of the subject. An area of localization of the moiety within the subject but outside the proximal tubules of the kidney identifies colorectal adenoma or carcinoma.

[09] According to yet another method for detection of colorectal adenoma or carcinoma, a substrate for renal dipeptidase is administered to a subject. The substrate is labeled with a detectable moiety. Feces are isolated from the subject. Renal dipeptidase reaction product or renal dipeptidase substrate with the detecable moiety is detected in the feces. An increased reaction product or decreased reaction substrate in the feces indicates colorectal adenoma or carcinoma in the subject.

[10] Still another method for detection of colorectal adenoma or carcinoma is provided by the present invention. A substrate for renal dipeptidase is administered to a subject. The substrate is labeled with a detectable moiety. Blood from the subject is subsequently isolated. Renal dipeptidase reaction product or renal dipeptidase substrate with the detecable moiety is detected in the blood. An increased product or decreased substrate in the blood indicates colorectal adenoma or carcinoma in the subject.

[11] Still another embodiment of the invention is a method for detection of colorectal adenoma or carcinoma. Renal dipeptidase in blood of a subject is detected and compared to the amount of renal dipeptidase in normal subjects. An elevated

amount of renal dipeptidase in the blood of the subject is an indicator of colorectal adenoma or carcinoma in the subject.

[12] Still another embodiment of the invention is a method for detection of colorectal adenoma or carcinoma. Renal dipeptidase in feces of a subject is detected and compared to the amount of renal dipeptidase in normal subjects. An elevated amount of renal dipeptidase in the feces of the subject is an indicator of colorectal adenoma or carcinoma in the subject.

[13] Yet another embodiment of the invention is a method for detection of colorectal adenoma or carcinoma. An mRNA sample is isolated from feces of a subject. Macrophage inhibitory cytokine mRNA is detected in the mRNA sample. The amount of macrophage inhibitory cytokine mRNA in said mRNA sample is compared to amounts of macrophage inhibitory cytokine mRNA in normal subjects. An elevated amount of macrophage inhibitory cytokine mRNA in said mRNA sample is an indicator of colorectal adenoma or carcinoma in the subject.

[14] Another embodiment of the invention is a method for detection of colorectal adenoma or carcinoma. Epithelial cells are isolated from blood of a subject. An mRNA sample is isolated from the epithelial cells. Macrophage inhibitory cytokine mRNA is detected in said mRNA sample. The amount of macrophage inhibitory cytokine mRNA in said mRNA sample is compared to amounts of macrophage inhibitory cytokine mRNA in normal subjects. An elevated amount of macrophage inhibitory cytokine mRNA in said mRNA sample is an indicator of colorectal adenoma or carcinoma in the subject.

[15] Still another embodiment of the invention is a method for detection of colorectal adenoma or carcinoma. Macrophage inhibitory cytokine in blood of a subject is detected and compared to the amount of macrophage inhibitory cytokine in normal subjects. An elevated amount of macrophage inhibitory cytokine in the blood of the subject is an indicator of colorectal adenoma or carcinoma in the subject.

[16] Still another embodiment of the invention is a method for detection of colorectal adenoma or carcinoma. Macrophage inhibitory cytokine in feces of a subject is detected and compared to the amount of macrophage inhibitory cytokine in normal subjects. An elevated amount of macrophage inhibitory cytokine in the feces of the subject is an indicator of colorectal adenoma or carcinoma in the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

[17] Fig. 1.*A*, Distribution of the fold changes of differentially expressed transcript tags. Transcripts in which the significance criterion was met ($p<0.05$, a total of 957 tags) in the comparisons between normal and adenoma or normal and cancer are plotted in the figure. The ratios of adenoma to normal and cancer to normal were plotted on a log scale. The shaded box in (Fig. 1.*A*) and enlarged in (Fig. 1.*B*) encloses the transcript tags detailed in Table 3. The two unlabeled dots correspond to tags whose differential expression could not be confirmed by quantitative PCR suggesting that the tags were derived from different transcripts than the ones indicated in Table 3.

[18] Fig. 2. Quantitative PCR analysis of genes elevated in both adenomas and cancers. Quantitation of expression of genes in tumors and matched normal tissues from five patients (Pt) are shown as fold elevation over that in matched normal colonic mucosa. Each bar represents the average of three independent measurements. *TGFBI*, *LYS*, *RDP*, *MIC-1*, *REGA*, and *DEHL* are as described in Table 3.

[19] Fig. 3. Quantitative PCR analysis of genes decreased in both adenomas and cancers. Quantitation of expression of genes in tumors and matched normal tissue from five patients (Pt) are shown as a fraction of matched normal. Each bar represents the average of three independent measurements. *CA2* and *DRA* are described in Table 4. Dual Specificity Phosphatase (*DUSP1*), and Acid Sphingomylenase-like phosphodiesterase (*ASML3a*) represented transcripts that were repressed but did not meet the stringent criteria required for inclusion in Table 4. SAGE data indicated

that *DUSP1* was 5- and 76-fold repressed in adenomas and cancers, respectively. *ASML3a* was 15-fold repressed in both adenoma and cancer.

[20] Fig. 4. Quantitative PCR analysis of mRNA from purified epithelial cells of genes elevated in both adenomas and cancers. Quantitation of expression of genes in the purified normal (N) or cancer (Ca) epithelial cells taken from two patients are shown as fold elevation over matched normal. Genes examined were the same as in Fig. 2.

[21] Fig. 5A – Fig. 5E. *In-situ* hybridization analyses of elevated genes. Genes examined were *REGA* (Fig. 5A), TGFBI (Fig. 5B), *LYS* (Fig. 5C), *RDP* (Fig. 5D), and *MIC-1* (Fig. 5E). Positive cells appear red, arrows point to clusters of malignant epithelial cells, and arrow heads point to macrophages.

[22] Fig. 6. Inhibitors of renal dipeptidase demonstrate inhibition constants ranging from 0.6 nM to 19.5 nM.

[23] Fig. 7. A comparison of the inhibitors shown in Fig. 6. compares the inhibition rate as a function of concentration of inhibitor.

[24] Fig. 8. Substrates of renal dipeptidase are shown.

[25] Fig. 9 shows the difference in activity of renal dipeptidase found in adenomas, cancer, and metastases compared to normal colonic tissue.

DETAILED DESCRIPTION OF THE INVENTION

[26] It is a finding of the present invention that particular genes are aberrantly and consistently expressed in both adenomas and carcinomas of the colon. Products of such genes provide cellular and serum markers for colorectal neoplasia. The ideal tumor marker would be expected to have several characteristics. First, it should be expressed at high levels in tumors and at greatly reduced levels in normal tissues. Second the elevated expression should occur early and remain elevated during the neoplastic process. Third, such a marker should be elevated in the majority of clinical samples. Fourth, the marker should be cell surface or secreted to facilitate its

detection. We have identified several genes that appear to meet all of these criteria and may therefore be especially useful as diagnostic tools for the early detection of colorectal neoplasia, even of presymptomatic colorectal neoplasia. Any of the markers identified in Tables 3 and 5 can be used, particularly Renal Dipeptidase and Macrophage Inhibitory Cytokine.

[27] Serum markers can be found and detected in whole blood, serum, plasma, or fractions thereof. These are collectively referred to as "blood" herein. Markers can also be found in stool. Samples for testing can be feces or processed or fractionated feces. All such samples are referred to herein as "feces."

[28] Inhibitors of markers which are enzymes, such as Renal Dipeptidase, can be used as affinity reagents for labeling the marker. Preferably the inhibitors are those which bind irreversibly. Alternatively they are ones which bind and release, but release at a slow rate. Inhibitors with suitably slow release rates are those which have a binding half-life of greater than 30 minutes, or 1, 2, 3, 5, 8, or 10 hours. Many inhibitors of Renal Dipeptidase are known, including the commercially available Cilastatin, and phosphinic acid inhibitors. See Parsons et al., "A new class of potent, slowly reversibly dehydropeptidase inhibitors," *Biochemistry International*, vol. 23, pp. 1107-1115, 1991. Inhibitors which covalently bind to and/or modify Renal Dipeptidase are also known and can be used. See Wu and Mobashery, "Targeting renal dipeptidase (dehydropeptidase I) for inactivation by mechanism-based inactivators," *J. Med. Chem.*, vol. 34, pp. 1914-1916, 1991. Some inhibitors mimic transition states between substrates and product. Some useful inhibitors are shown in Fig. 6. These include inhibitors having halogen substitutions. Such inhibitors can be readily made using radioactive halogens for ready labeling of renal dipeptidase and easy detection. Similar inhibitors of other enzymes are also known in the art and can be used. Inhibitors can be labeled using any detectable moiety known in the art, including but not limited to fluors and radioactive atoms.

[29] RNA for any of the markers can be detected using any of the known techniques in the art. Preferably an amplification step will be used, because the amount of RNA

for the marker is expected to be very small from the sources contemplated. Suitable techniques include RT-PCR, hybridization of copy mRNA (cRNA) to an array of nucleic acid probes, and Northern blotting.

[30] Protein forms of the markers can be detected using any techniques known in the art. These include activity assays, immunological assays, binding to specific ligands, etc. Particularly suitable assays for Renal Dipeptidase include using L-L amino acid dipeptide substrates and L-D amino acid dipeptide substrates. Substrates which can be used for assaying renal dipeptidase are shown in Fig. 8, and include the generic structures for dipeptides and dehydrodipeptides. ε (DNP)-L-Lysine-D -Amp can also be used as a substrate, yielding a colored product. Substrates for other enzymes can be used similarly to assess the presence of the tumor marker enzyme in the body or in a body sample. Such substrates can be labeled with detectable moieties, including but not limited to fluors and radioactive atoms. One particularly useful labeling scheme employs a substrate which is labeled with two moieties on opposite sides of the substrate cleavage site. One of the moieties is fluorescent and one of the moieties is a quencher. When the two moieties are close, as in an intact substrate, the fluorescence of the fluorescent moiety is quenched. Upon cleavage the quenching is released and an increase in fluorescence is observed.

[31] As mentioned above, inhibitors can also be labeled and used for detecting suitable markers. In addition, antibodies can be used to label protein forms of the markers. The antibodies can be labeled as is known in the art. Suitable radioactive atoms for use in labeling inhibitors, substrates, and antibodies include In-111, I-123, Tc-99m, Re-186, Re-188, Ga-67, Ga-68, Tl-201, Fe-52, Pb-203, Co-58, Cu-64, I-124, I-125, I-131, At-210, Br-76, Br-77, and F-18 and others known in the art for such purposes. Contrast enhancement agents can also be attached to the substrates, inhibitors, or antibodies. Such agents include gadolinium. Moreover, imaging techniques can be used to detect such labels within the body. An example of an imaging technique which can be used is spiral computer tomography. For this technique, the detecting agent, such as inhibitor or antibody can be linked to a contrast enhancing agent.

Other detection means that can be used include gamma cameras, magnetic resonance imaging, planar scintigraphic imaging, SPECT imaging, PET imaging, and ultrasound imaging. Thus markers can be detected both *in situ* in the body or *in vitro* in an isolated body sample.

[32] Epithelial cells can be isolated from blood or other tissue samples to enrich for the markers or their mRNAs. Epithelial cells can be isolated, *inter alia,* by immunoaffinity techniques. Such a technique is described in more detail below.

[33] Substrates of enzymic markers can be administered to subjects and the reaction products measured in body samples. Inhibitors can be administered to subjects and the subject can be imaged to detect the inhibitor bound to the marker. Such markers are preferably those which are not secreted proteins, but rather are those which are anchored to a tumor. Typical modes of administration of such agents can be any which is suitable, including but not limited to per os, intravenous, intramuscular, intraarterial, subdermal, transdermal, and rectal.

[34] A high background of certain markers may obscure detection of increased expression. In such a situation, one can use tumor-specific glycoforms as a means of distinguishing between the background marker and the marker that is due to the tumor. Tumor-specific glycoforms of Renal Dipeptidase and MIC-1 bind to LPHA, an L lectin from Phaseolus vulgaris hemagglutinin, and thus can be distinguished on that basis. Other lectins such as with similar specificity for tumor-specific glycoforms, such as Sambucus Nigra Lectin isolated from Sambucus nigra (elderberry) bark can be used as well.

[35] Normal subjects are used as a comparison to the test subjects to determine whether the amounts of markers observed in the feces or blood are elevated. Preferably the normal subjects have been confirmed as tumor-free by colonoscopy. More preferably several samples are pooled or their individual values are averaged to arrive at a normal value.

[36] Some of the most highly overexpressed genes found in colorectal adenomas and colorectal cancers are discussed below. Regenerating Islet Derived Pancreatic Stone Protein, encoded by the *REGA* gene, is a secreted polypeptide first found in pancreatic precipitates and stones from patients suffering from chronic pancreatitis (7). The cDNA encoding this protein was isolated from a random screen of genes highly expressed in a regenerating-islet derived cDNA library (8) and subsequently shown to be elevated in colorectal cancers (9). More recently, *REGA* was isolated in a hybridization-based screen for genes elevated in colorectal cancers and shown to be elevated in many colorectal adenocarcinomas (10). Consistent with these published observations, we observed a strong elevation in expression of *REGA* in unpurified tumors, and a similar elevation in one purified tumor. *In situ* hybridization experiments demonstrated *REGA* to be strongly expressed in the epithelial cells of the tumors, with no expression evident in the stroma (Fig. 5A).

[37] TGFB-induced gene (*TGFBI*) encodes a small polypeptide of unknown function initially isolated through a differential display screen for genes induced in response to treatment with TGF β (11). The protein is expressed in the keratinocytes of the cornea (12) and, interestingly, germline mutations of this gene cause familial corneal dystrophies (13). *TGFBI* was previously shown to be among the most significantly elevated genes in colorectal cancers (4), and our new data show that it is expressed at high levels in adenomas as well. Quantitative PCR results demonstrated strong elevation both in unpurified tumors and purified tumor epithelial cells. Accordingly, *in situ* hybridization experiments revealed *TGFBI* to be expressed in many cell types, in both the stromal and epithelial compartments (Fig. 5B).

[38] Lysozyme (*LYS*, 1,4-β-N-acetylmuramidase, EC 3.2.1.17) is an enzyme with bacteriolytic activity (14) capable of cleaving β-1,4 glycosidic bonds found in the cell walls of gram-positive bacteria. The enzyme is expressed in the secretory granules of monocytes, macrophages and leukocytes, as well as in the Paneth cells of the gastrointestinal tract. Fecal lysozyme levels are dramatically elevated in patients with inflammatory bowel disease (15, 16), and serum lysozyme activity is

significantly elevated in patients with sarcoidosis (17), both of which are diseases characterized by aberrant chronic inflammation. Furthermore, lysozyme immunoreactivity has been observed in the epithelial cells of both adenomas and carcinomas of the large intestine (18). In our study, the degree of elevation of expression of *LYS* varied from 4-fold to 55-fold in the unpurified samples. In contrast, the degree of elevation of expression of *LYS* observed in purified epithelial cells was only 2-5 fold. This suggested that a substantial portion of the expression for this gene in the tumors could have been derived from non-epithelial cells. Consistent with this hypothesis, *in situ* hybridization experiments revealed that the majority of *LYS* mRNA was present in a stromal component that appeared to be macrophages (Fig. 5C). The expression of *LYS* in the macrophage compartment of colorectal tumors was also supported by its high representation in a SAGE library constructed from hematopoietic cells (CD45+, CD64+, CD14+) purified from colorectal tumors (602 *LYS* tags/56,643 total tags) (6).

[39] One interesting gene identified in the current study is renal dipeptidase (*RDP*). *RDP* is a GPI-anchored enzyme whose major site of expression is the epithelial cells of the proximal tubules of the kidney (reviewed in (19)). The enzyme has been extensively analyzed with respect to its catalytic mechanism and inhibition kinetics by a variety of synthetic inhibitors. *RDP* is unique among the dipeptidases in that it can cleave amide bonds in which the C-terminal partner is a D amino acid, providing excellent opportunity for the development of specific probes for its detection *in vivo*. Quantitative PCR revealed *RDP* to be markedly elevated in both unpurified and purified tumor epithelial cells, and *in situ* hybridization experiments showed that *RDP* was exclusively localized to epithelial cells of colorectal tumors (Fig. 5D).

[40] Macrophage Inhibitory Cytokine (MIC-1) is a small polypeptide of 16 kDa first isolated from a differential screen for genes that were induced upon macrophage activation (20). Concurrently, it was identified in the IMAGE database by a search for molecules homologous to the Bone Morphogenic Protein/TGF β family of growth and differentiation factors (21). In addition to being highly expressed in

activated macrophages, *MIC-1* has been noted to be highly expressed in placenta and the epithelial cells of normal prostate. In the current study, we found *MIC-1* expression to be elevated between 7 and 133 fold in the unpurified tumors. As observed for *LYS*, the purified tumor cells demonstrated significant but less elevation of expression of *MIC-1* (5 to 7-fold) indirectly implicating stromal expression to be partly responsible for the dramatic elevation seen in some tumors. Consistent with this hypothesis, *in situ* hybridization experiments revealed expression in both the epithelium of the tumor, and in a cell type resembling infiltrating macrophages (Fig. 5E).

Examples

Example1: SAGE

[41] In an effort to identify potential molecular markers of early colorectal tumors, we have here analyzed gene expression in benign and malignant colorectal tumors in an unbiased and comprehensive fashion. We used SAGE to analyze global gene expression in normal, benign and malignant colorectal tissue. SAGE is a gene expression profiling method that associates individual mRNA transcripts with 15-base tags derived from specific positions near their 3' termini (3). The abundance of each tag provides a quantitative measure of the transcript level present within the mRNA population studied. SAGE is not dependent on pre-existing databases of expressed genes, and therefore provides an unbiased view of gene expression profiles. For the current study, SAGE libraries derived from two samples of normal colonic epithelium, two colorectal adenomas, and two colorectal cancers were analyzed. These libraries contained a combined total of 290,394 transcript tags representing 21,343 different transcripts (Table 1).

Tables 1– Summary of SAGE data

SAGE Library	Total number of tags observed	Number of different transcripts observed *
Normal Colorectal Epithelium		
NC-1	49,610	9,359
NC-2	48,479	9,610
Adenomas		
Ad-A	52,573	11,167
Ad-B	42,661	9,483
Cancers		
Tu-98	41,371	9,780
Tu-102	55,700	11,039
Total	**290,394**	**21,343**

* To minimize the effect of potential sequencing errors, only tags observed more than once in a given SAGE library were counted to give a conservative estimate of the minimum number of different transcripts analyzed.

[42] Two comparisons were performed, one between the adenoma and normal samples, and one between the cancer and normal samples. These comparisons revealed 957 transcript tags that were differentially expressed more than 2-fold between normal and tumor tissue (Table 2). A comparison of the fold change in adenomas versus cancers revealed that many transcripts were similarly elevated or repressed in both adenomas and cancers although the magnitude often varied (Fig. 1A). Indeed the majority (79%) of comparisons were in quadrants of the plot indicative of concordant elevation.

Table 2 – *Differentially expressed transcripts in benign and malignant tumor colorectal tissue*

Fold change in expression	Elevated in adenomas[a]	Elevated in cancers[a]	Elevated in both adenomas and cancer[a]	Repressed in adenomas[b]	Repressed in cancers[b]	Repressed in both adenomas and cancers[b]	Total transcripts differentially expressed
2	346	170	50	313	380	192	957
4	263	119	23	225	270	117	735
10	160	79	10	134	157	58	462
20	49	40	9	72	52	23	181

[a] Elevated transcripts showed a significantly different ($P<0.05$) tag count between normal and tumor tissue, were expressed in both tumor tissues analyzed, and had an expression level that was higher in the tumors than in the normals by the fold indicated in column one. For the purposes of calculation, 0.5 was substituted for the denominator when no tags were detected in the normal samples.

[b] Repressed transcripts showed a significantly different ($P<0.05$) tag count between normal and tumor tissue, were expressed in both normal tissues analyzed and had an expression level that was lower in the tumors than in the normals by the fold indicated in column one.

[43] From both practical and biological perspectives, those changes showing the greatest magnitude were deemed the most interesting. In this regard, 49 tags were identified to be elevated by ≥20-fold in the adenomas and 40 were elevated by ≥20-fold in the cancers (Table 2). Conversely, there were 72 transcripts that were decreased by ≥20-fold in adenomas and 52 decreased by ≥20-fold in the cancers (Table 2).

[44] There were nine transcripts that were elevated by ≥20-fold in both adenomas and cancers (Fig. 1B and Table 3) and 23 that were repressed by ≥20-fold (Table 4). We were especially interested in genes whose products were predicted to be secreted or displayed on the cell surface, as these would be particularly suitable for the development of serologic or imaging tests for presymptomatic neoplasia, respectively. We were able to identify six such genes (*TGFBI*, *LYS*, *RDP*, *MIC-1*, *REGA* and *DEHL*) from among those whose transcript tags were elevated in both adenoma and carcinoma SAGE libraries.

Table 3. Transcripts most elevated in adenomas and cancers[a]

Tag Sequence	Normal		Adenomas		Cancers		Transcript name
	NC-1	NC-2	AD-A1	AD-B2	Tu-98	Tu-102	
ATGTAAAAAA	**0**	**0**	**26**	**32**	**2**	**12**	**Lysozyme (*LYS*)**
TAATTTTTGC	**0**	**1**	**99**	**12**	**20**	**37**	**Differentially Expressed in Hematopoietic Lineages (*DEHL*)**
GTGTGTTTGT	**0**	**0**	**17**	**29**	**17**	**15**	**Transforming Growth Factor, Beta-Induced (*TGFBI*)**
GTGCTCATTC	**0**	**0**	**13**	**7**	**2**	**10**	**Macrophage Inhibitory Cytokine, 1 (*MIC-1*)**
TTCCAGCTGC	0	0	7	6	2	9	Adaptor-related Protein Complex 2, alpha 2 subunit[b]
ACCATTGGAT	0	0	3	10	3	9	Interferon Induced Transmembrane Protein 1 (9-27)[b]
TTTCCACTAA	**0**	**0**	**8**	**4**	**4**	**6**	**Regenerating Islet-Derived 1 alpha (*REGA*)**
CAAGGACCAG	**0**	**0**	**5**	**6**	**10**	**12**	**Renal Dipeptidase (*RDP*)**
AGGACCATCG	0	0	8	2	1	18	Defensin, Alpha 5, Paneth cell-specific[c]

[a] These tags displayed at least twenty fold elevation in both neoplastic states. The numbers given are the raw tag counts for each tag observed in each library. Transcript name provides a description of matching UniGene cluster (Build 3/13/01). Rows shown in bold are genes confirmed by quantitative PCR to be differentially expressed.

[b] Differential expression could not be confirmed by quantitative PCR suggesting that the tag was derived from a different transcript than the one indicated.

[c] Not tested.

Table 4. Transcripts most repressed in adenomas and cancers[a]

	Normal		Adenoma		Cancer			
Tag Sequence	NC-1	NC2	AD-A1	AD-B	Tu-981	Tu-102	UNI ID	Transcript name
GTCATCACCA	35	22	0	0	0	0	32966	Guanylate Cyclase Activator 2B
CCTTCAAATC	29	17	0	0	1	0	23118	Carbonic Anhydrase I
TCTGAATTAT	24	16	0	0	1	0	50964	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1
TTATGGTGTG	11	17	0	0	0	0	271499	ESTs
CTGGCAAAGG	14	22	1	0	0	0	72789	hypothetical protein FLJ20217
AGGTGACTGG	10	14	0	0	0	0		No Match
CTTATGGTCC	36	11	0	1	1	0	179608	Retinol Dehydrogenase Homolog
ATGATGGCAC	12	32	1	0	1	0	84072	Transmembrane 4 Superfamily Member 3
GTCCGAGTGC	17	3	0	0	0	0	3337	Transmembrane 4 Superfamily Member 1
ATTTCAAGAT	**35**	**21**	**0**	**2**	**1**	**0**	**155097**	**Carbonic Anhydrase II (*CA2*)**
CAAGAGTTTC	14	2	0	0	0	0	183617	ESTs
GCCATCCTCC	9	13	0	1	0	0		No Match
ACCCAACTGC	12	3	0	0	0	0	232604	Homo sapiens cDNA: FLJ22675 fis, clone HSI10553
GCCCACGTCA	7	8	0	0	0	0		No Match
TTTGGTTTCA	2	13	0	0	0	0		No Match
CTCAGAACTT	18	3	1	0	0	0	194710	N-acetylglucosaminyl transferase 3, mucin type
CCAACACCAG	9	19	1	0	0	1	181165	Eukaryotic Translation Elongation Factor 1 Alpha 1
GCCACATACT	3	9	0	0	0	0	4984	KIAA0828 protein
GTATTGGGGC	5	7	0	0	0	0		No Match
CCGGCTTGAG	7	4	0	0	0	0	2722	Inositol 1,4,5-trisphosphate 3-Kinase A
GATATGTAAA	1	10	0	0	0	0	227059	Chloride Channel, Calcium Activated, Family Member 4
CATAGGTTTA	**66**	**39**	**4**	**1**	**5**	**0**	**1650**	**Solute Carrier Family 26, member 3 (*DRA*)**
GTCCTGAACA	7	3	0	0	0	0	78546	ATPase, Ca++ Transporting, Plasma Membrane 1

[a] These tags displayed at least twenty fold decrease in both neoplastic states. The numbers given are the raw tag counts for each tag observed in each library. Transcript name provides a description of matching UniGene cluster (Build 3/13/01). Rows shown in bold are genes that were tested and confirmed by quantitative PCR to be differentially expressed.

[45] **SAGE.** For the initial SAGE[3] of benign tumors, fresh adenomas were obtained from surgical specimens derived from FAP patients. Adenomas from FAP patients were employed because of the ready availability of small lesions and the certainty of inactivation of the APC pathway which initiates the formation of the majority of sporadic tumors. After histopathological verification of the neoplastic nature of the lesion (>70% neoplastic cells), total RNA was isolated by solubilizing the tissue in RNAgents Lysis Buffer (Promega, Madison, WI) followed by ultracentrifugation over a cesium chloride gradient. mRNA selection was performed from the purified total RNA using oligo(dT) cellulose (Life Technologies, Gaithersburg, MD). Two adenoma SAGE libraries were prepared as described (3, 4) and sequenced to a total depth of over 90,000 transcript tags. For SAGE of normal and malignant tissues, four previously described normal (NC-1 and NC-2) and primary cancer (Tu-98 and Tu-102) SAGE libraries were employed (4). In collaboration with the Cancer Genome Anatomy Project (CGAP) (5), the analyses of these libraries was extended from a total of 123,046 transcripts in the previously published work to 195,160 transcripts in the current work. Tags were extracted from the raw sequence data and, after excluding repeated ditags, linker sequences, and tags from the polymorphic Major Histocompatibility loci, the resulting tag libraries were compared and statistical analysis performed using SAGE software, version 4.0 . Data from the libraries are publicly available at the Uniform Resource Locator (URL) address for the http file type found on the www host server that has a domain name of ncbi.nlm.nih.gov, and a path to the directory SAGE, and detailed SAGE protocols are available at the Uniform Resource Locator (URL) address for the http file type found on the www host server that has a domain name of sagenet.org, and file name of sage_protocol.htm.

Example 2: RT-PCR

[46] To verify the increased expression of these six genes, we used quantitative RT-PCR techniques to analyze the expression in seven colorectal neoplasms (three sporadic adenomas and four sporadic cancers) and matched normal colonic mucosa. For these assays, specific primers were developed that resulted in

amplification from cDNA but not genomic DNA. Controls were provided by similar quantitative PCR assays of a gene whose expression was found to be very similar in the SAGE libraries of normal and neoplastic colon (β-amyloid precursor protein). The quantitative PCR experiments verified that five of the six selected genes (*TGFBI*, *LYS*, *RDP*, *MIC-1*, *REGA*) were expressed at significantly higher levels in every neoplastic sample analyzed compared to patient-matched normal mucosa (Fig. 2). Several tumors exhibited ≥20-fold higher levels of the studied transcripts compared to their patient-matched normal colonic mucosa, as predicted by SAGE. Another control was provided by the quantitative PCR analysis of four genes whose expression was observed to be reduced in the SAGE libraries prepared from adenomas and cancers compared to those from normal colonic mucosa. As shown in Fig. 3, the quantitative PCR confirmed the lower levels of expression of each of these genes, emphasizing that the dramatic elevations in expression observed in Fig. 2 represented gene-specific phenomena.

[47] **Quantitative PCR.** Tumors were collected, snap frozen, and stored at –80°C. They were verified to be predominantly composed of neoplastic cells by histopathological analysis. mRNA was isolated from tumors and patient-matched normal colonic mucosa using QuickPrep reagents (Amersham Pharmacia Biotech UK, Buckinghamshire, England), and single-stranded cDNA was synthesized using Superscript II (Life Technologies, Gaithersburg, MD). Quantitative PCR was performed using an iCycler (Bio-Rad, Hercules, CA), and threshold cycle numbers determined using iCycler software, version 2.1. Reactions were performed in triplicate and threshold cycle numbers averaged. All genes examined were normalized to a control gene (□-amyloid precursor protein, shown by SAGE to be expressed at equivalent levels in all colorectal samples), and fold induction calculated according to the formula $2^{(Rt-Et)}/2^{(Rn-En)}$ where Rt is the threshold cycle number for the Reference gene observed in the tumor, Et is the threshold cycle number for the Experimental gene observed in the tumor, Rn is the threshold cycle number for the Reference gene observed in the normal, and En is the threshold cycle number for the Experimental gene observed in the

normal. The primers used for quantitative PCR were obtained from GeneLink (Hawthorne, NY), and their sequences are available upon request.

Example 3: Expression in isolated epithelial cells

[48] The quantitative PCR data obtained from mRNA isolated from whole tumors provided independent evidence that SAGE provided an accurate indication of gene expression changes in colorectal neoplasia. However, neither analysis identified the cell types responsible for the increased expression. Non-neoplastic stromal cells within tumors may be considerably different than those in normal colonic mucosa (6), and the epithelial derivation of gene expression differences cannot reliably be concluded without direct supporting evidence. We therefore sought to determine if the epithelial cells of cancers express elevated levels of the six genes depicted in Fig. 2. First, we affinity-purified cancerous and patient-matched normal epithelial cells from fresh surgical specimens using immunomagnetic beads directed to the pan epithelial marker Ber-EP4, prepared cDNA and performed quantitative PCR analysis to determine the expression levels of the elevated genes as above. Elevated expression was observed in the purified tumor epithelial cells for each of the six genes examined (Fig. 4), demonstrating that at least some of the increased expression was derived from epithelial cells. However, relative expression of *LYS* was not as prominent or reproducible in the purified epithelial cells as in the mRNA from the unfractionated tumors, suggesting that other cell types might have contributed transcripts from this gene.

[49] **Epithelial cell immunoaffinity purification.** Tumor epithelial cells were purified using a modification of the procedure previously developed for the isolation of tumor endothelial cells (6). In brief, fresh surgical specimens of tumor and matched normal tissue were obtained and digested with collagenase and the resulting material filtered through a nylon mesh to obtain single cell suspensions. The cells were then bound to a mixture of anti-CD14 and anti-CD45 immunomagnetic beads (Dynal, Oslo, Norway) to deplete the population

of hematopoetic cells (negative selection). The remaining cell suspension was then incubated with anti-Ber-EP4 immunomagnetic beads to isolate epithelial cells (positive selection). Purified cells were lysed directly on the beads and mRNA purified using QuickPrep reagents (Amersham Pharmacia Biotech UK, Buckinghamshire, England).

Example 4: *In situ* hybridization in multiple tumors

[50] We performed *in situ* hybridization to RNA in frozen sections of tumors for five of the genes showing the most consistent elevation. *DEHL* was found to be elevated in only five of the nine tumors examined and was not investigated further. To increase the sensitivity of detection, we generated several RNA probes for each tested gene using *in vitro* transcription techniques. The results obtained are discussed below in conjunction with brief overviews of each of the five genes of interest.

[51] ***In situ* Hybridization.** Non-radioactive *in situ* hybridization was performed as described (6). For each gene analyzed, a cocktail of anti-sense probes made through *in vitro* transcription were employed to increase sensitivity. The primers used to generate templates for the synthesis of the *in situ* riboprobes were obtained from GeneLink (Hawthorne, NY), and their sequences are available upon request.

[52] The results summarized above show that although a large number of tags are observed in the colorectal tissues analyzed, only a small fraction (957/21,343, <5%) were expressed differentially in benign or malignant neoplastic tissues. A similarly small fraction of genes (66/4000, 1.7%) were found to be aberrantly expressed in colorectal neoplasms using oligonucleotide arrays (22). Analysis of these differentially expressed genes not only has the potential to provide insights into the biology of human neoplasia but also may have clinically useful applications. One of the most exciting potential applications concerns the identification of genes whose products provide cellular and serum markers for colorectal neoplasia. In the current study, we identified several genes that

appeared to meet all of these criteria and may therefore be especially useful as diagnostic tools for the early detection of presymptomatic colorectal neoplasia. Indeed, the product of one of these genes (MIC-1), has recently been found to be elevated in the serum of patients with colorectal and other cancers, providing further validation of this approach (24).

[53] While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention as set forth in the appended claims.

UP - 1

TABLE 5

Tag_Sequence	NC1	NC2	AD1	AD2	CA1	CA2	UNI ID	Description
AAAAGAAACT	1	3	33	52	7	16	172182	poly(A)-binding protein, cytoplasmic 1
AACGAGGAAT	8	0	24	26	17	23		
AAGAAGATAG	6	6	28	25	21	34	184776	ribosomal protein L23a
AATAGGTCCA	12	9	32	36	22	22	113029	ribosomal protein S25
ACAACTCAAT	1	1	7	7	8	6	244125	EST
ACAACTCAAT	1	1	7	7	8	6	75922	brain protein I3
ACATCATCGA	10	18	50	66	34	46	182979	ribosomal protein L12
ACCATTGGAT	0	0	3	10	3	9	146360	interferon induced transmembrane protein 1 (9-27)
ACCTGTATCC	5	3	20	6	26	35	182241	interferon induced transmembrane protein 3 (1-8U)
ACTCCAAAAA	9	12	21	65	21	37	133230	ribosomal protein S15
AGCACCTCCA	37	37	108	81	57	108	75309	eukaryotic translation elongation factor 2
AGGACCATCG	0	0	8	2	1	18		
AGGGCTTCCA	26	41	74	108	50	85	29797	ribosomal protein L10
ATGGCTGGTA	18	46	79	75	81	136	182426	ribosomal protein S2
ATGTAAAAAA	0	0	26	32	2	12	178112	DNA segment, single copy probe LNS-CAI/LNS-CAII (deleted in polyposis
ATGTAAAAAA	0	0	26	32	2	12	234734	lysozyme (renal amyloidosis)
ATGTAAAAAA	0	0	26	32	2	12	83715	Sjogren syndrome antigen B (autoantigen La)
ATTCTCCAGT	8	20	20	48	43	28	234518	ribosomal protein L23
CAAGGACCAG	0	0	5	6	10	12	109	dipeptidase 1 (renal)
CAATAAATGT	8	6	40	76	33	67	179779	ribosomal protein L37
CAGCTCACTG	4	17	9	35	21	24	158675	ribosomal protein L14
CATTTGTAAT	48	27	102	57	36	125		
CCTAGCTGGA	16	27	58	45	48	66	182937	peptidylprolyl isomerase A (cyclophilin A)
CCTTCGAGAT	6	12	13	29	7	41	76194	ribosomal protein S5
CTCCTCACCT	7	13	38	36	24	75	242908	lecithin-cholesterol acyltransferase
CTGACTTGTG	0	0	1	20	9	2	77961	major histocompatibility complex, class I, B
CTGGGTTAAT	14	24	84	83	42	112	126701	ribosomal protein S19
CTGTTGATTG	13	3	60	38	32	27	249495	heterogeneous nuclear ribonucleoprotein A1
CTGTTGGTGA	9	19	37	59	31	61	3463	ribosomal protein S23
GAAAAATGGT	7	12	49	47	25	27	181357	laminin receptor 1 (67kD, ribosomal protein SA)
GAGTCAGGAG	2	0	8	6	9	7	181271	CGI-120 protein
GCATAATAGG	11	16	22	54	50	21	184108	ribosomal protein L21 (gene or pseudogene)

Up-2

GCATTTAAAT	1	2	10	18	12	7	261802	eukaryotic translation elongation factor 1 beta 1
GCATTTAAAT	1	2	10	18	12	7	275959	eukaryotic translation elongation factor 1 beta 2
GCATTTGACA	2	5	27	17	9	20	172129	Homo sapiens cDNA: FLJ21409 fis, clone COL03924
GCTTTTAAGG	2	8	14	32	16	17	8102	ribosomal protein S20
GGACCACTGA	18	39	76	57	48	83	119598	ribosomal protein L3
GGGGGTAACT	1	2	8	11	14	13	99969	fusion, derived from t(12;16) malignant liposarcoma
GTGCGCTGAG	0	0	75	0	20	18	277477	major histocompatibility complex, class I, C
GTGCTCATTC	0	0	13	7	2	10	116577	prostate differentiation factor
GTGCTCATTC	0	0	13	7	2	10	25945	ESTs
GTGTGTTTGT	0	0	17	29	17	15	118787	transforming growth factor, beta-induced, 68kD
GTTCGTGCCA	1	13	18	43	24	18	179606	nuclear RNA helicase, DECD variant of DEAD box family
GTTCGTGCCA	1	13	18	43	24	18	179666	uncharacterized hypothalamus protein HSMNP1
TAATAAAGGT	4	11	37	62	24	27	151604	ribosomal protein S8
TAATTTTTGC	0	1	99	12	20	37	273321	differentially expressed in hematopoietic lineages
TCACAAGCAA	10	7	17	21	13	38	146763	nascent-polypeptide-associated complex alpha polypeptide
TCAGATCTTT	14	32	37	108	31	87	75344	ribosomal protein S4, X-linked
TCCTGCCCCA	1	5	10	14	7	16	171814	parathymosin
TGAAATAAAA	0	2	2	14	13	11	173205	nucleophosmin (nucleolar phosphoprotein B23, numatrin)
TGAAATAAAA	0	2	2	14	13	11	192822	Human DNA sequence from clone RP5-1179L24 on chromosome 6q24.3-25.3. Contains the 3' end of the gene for a novel protein similar to mouse phospholipase C neighboring protein PNG, ESTs, STSs and GSSs
TGATGTCTGG	0	0	2	6	8	2	83883	transmembrane, prostate androgen induced RNA
TGTAATCAAT	2	3	13	11	8	11	249495	heterogeneous nuclear ribonucleoprotein A1
TTACCATATC	10	5	22	30	26	22	300141	ribosomal protein L39
TTATGGGATC	6	4	24	37	36	47	5662	guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1
TTCAATAAAA	8	14	79	111	36	50	177592	ribosomal protein, large, P1
TTCCAGCTGC	0	0	7	6	2	9	112442	ESTs, Weakly similar to
TTCCAGCTGC	0	0	7	6	2	9	19121	adaptor-related protein complex 2, alpha 2 subunit
TTCCAGCTGC	0	0	7	6	2	9	227277	sine oculis homeobox (Drosophila) homolog 3
TTTCCACTAA	0	0	8	4	4	6	1032	regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein)
TTTCCACTAA	0	0	8	4	4	6	289088	heat shock 90kD protein 1, alpha
TTTTTAATGT	0	2	12	18	6	7	181307	H3 histone, family 3A

TABLE 6

Down-1

Tag_Sequence	NC1	NC2	AD1	AD2	CA1	CA2	UNI ID	Description
AAATCTGGCA	16	15	2	4	2	0	430	plastin 1 (I isoform)
AACGTGCAGG	29	31	13	6	7	8	160786	argininosuccinate synthetase
AAGAAAGCTC	20	6	0	2	1	5	25264	DKFZP434N126 protein
AAGAAAGCTC	20	6	0	2	1	5	91011	anterior gradient 2 (Xenepus laevis) homolog
AAGAAGCAGG	8	16	3	4	1	3	11441	chromosome 1 open reading frame 8
AAGGTAGCAG	15	16	2	4	2	4	104125	adenylyl cyclase-associated protein
AATAAAGGCT	25	11	3	7	3	4	179735	ras homolog gene family, member C
AATAGTTTCC	7	16	2	3	6	1	272620	pregnancy specific beta-1-glycoprotein 9
AATCACAAAT	18	45	1	4	14	3	74466	carcinoembryonic antigen-related cell adhesion molecule 7
AATGAGAAGG	11	3	0	0	1	0	198248	UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1
ACAATTGGTC	0	10	0	0	0	0	155097	carbonic anhydrase II
ACACCCATCA	2	27	1	0	5	3	110445	CGI-97 protein
ACAGGGTGAC	25	13	1	8	7	6	174050	endothelial differentiation-related factor 1
ACATTGGGTG	377	334	67	34	96	33	275086	PR domain containing 10
ACATTGGGTG	377	334	67	34	96	33	5241	fatty acid binding protein 1, liver
ACCCAACTGC	12	3	0	0	0	0	232604	Homo sapiens cDNA: FLJ22675 fis, clone HSI10553
ACCCACGTCA	22	10	3	5	3	1	198951	jun B proto-oncogene
ACCCCCCCGC	44	38	7	13	16	6	229413	ESTs
ACCCCCCCGC	44	38	7	13	16	6	2780	jun D proto-oncogene
ACCTGCATCC	0	12	0	0	0	0		
ACCTGGGGAG	35	11	1	3	4	3	131748	ESTs, Moderately similar to
ACCTGGGGAG	35	11	1	3	4	3	209119	1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)
ACGGTCCAGG	5	12	0	0	0	1	72924	cytidine deaminase
ACTCTTGTTG	7	2	0	0	0	0	5378	spondin 1, (f-spondin) extracellular matrix protein
ACTGTGGCGG	17	34	9	12	9	4	112242	ESTs
AGAATAGCTT	44	67	3	9	11	30	24133	ESTs
AGCAGGAGCA	50	14	6	3	7	6	178292	KIAA0180 protein
AGCAGGAGCA	50	14	6	3	7	6	738	early growth response 1
AGCCCGACCA	16	8	2	4	1	3	104114	H.sapiens HCG I mRNA
AGGATGGTCC	34	19	5	3	6	8	71779	Homo sapiens DNA from chromosome 19, cosmid F21856
AGGCCAAGGG	21	6	3	1	3	4	76057	galactose-4-epimerase, UDP-

Down-2

AGGTGACTGG	10	14	0	0	0	0		
AGTGGGCTCA	3	8	0	1	0	0		
ATACTCCACT	82	59	0	0	10	3	778	guanylate cyclase activator 1B (retina)
ATATAATCTG	18	14	1	4	5	5	621	lectin, galactoside-binding, soluble, 3 (galectin 3)
ATCGTGGCGG	193	92	19	25	20	10	5372	claudin 4
ATGACGCTCA	22	18	6	5	3	4	8254	hypothetical protein PRO0899
ATGATGGCAC	12	32	1	0	1	0	84072	transmembrane 4 superfamily member 3
ATGCGGAGTC	14	13	5	3	2	4	25527	tight junction protein 3 (zona occludens 3)
ATGCGGGAGA	38	39	15	22	5	6	109748	Homo sapiens CAC-1 mRNA, partial cds
ATGGCACGGA	6	21	1	1	3	0	81097	cytochrome c oxidase subunit VIII
ATGGTCTACG	10	5	0	0	1	0	96593	hypothetical protein
ATGGTGGGGG	25	30	11	9	1	2	1665	zinc finger protein homologous to Zfp-36 in mouse
ATGTGCGTGG	38	8	11	3	7	7	56937	suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin)
ATGTGGGCTC	7	2	0	0	0	0	151641	glycoprotein A repetitions predominant
ATGTGGGCTC	7	2	0	0	0	0	27018	Ris
ATTGGAGTGC	136	85	15	36	37	19	220529	carcinoembryonic antigen-related cell adhesion molecule 5
ATTTCAAGAT	35	21	0	2	1	0	155097	carbonic anhydrase II
ATTTCAAGAT	35	21	0	2	1	0	24453	ESTs
CAAATAAAAG	9	12	2	0	1	1	185055	BENE protein
CAAGAGTTTC	14	2	0	0	0	0	183617	ESTs
CACCCCTGAT	73	169	58	58	13	36	173724	creatine kinase, brain
CAGTGCGTTC	12	3	0	0	3	0	8302	four and a half LIM domains 2
CATAGGTTTA	66	39	4	1	5	0	1650	solute carrier family 26, member 3
CCAAAGCTAT	42	16	14	12	6	11	84072	transmembrane 4 superfamily member 3
CCAACACCAG	9	19	1	0	0	1	181165	eukaryotic translation elongation factor 1 alpha 1
CCACTGCACC	21	19	5	5	6	14		
CCAGGGGAGA	45	66	24	22	10	20	278613	interferon, alpha-inducible protein 27
CCATTCCACT	13	1	2	0	0	0		
CCCAACGCGC	106	1	3	5	0	2	272572	hemoglobin, alpha 2
CCCCCGAAGC	25	27	3	15	4	8	61265	ESTs, Weakly similar to
CCCCCGCGGA	33	25	6	11	4	12	95697	liver-specific bHLH-Zip transcription factor
CCCCCTGCAT	5	4	0	0	0	0		
CCCGCCTCTT	0	40	3	3	16	1	mito	Tag matches mitochondrial sequence

Down · 3

CCCTCCCGAA	89	54	9	14	18	7	5940	hypothetical protein FLJ20063
CCGCTGCACT	127	102	55	46	37	30		
CCGGCTTGAG	7	4	0	0	0	0	2722	inositol 1,4,5-trisphosphate 3-kinase A
CCTCCAGCTA	715	458	142	125	131	147	242463	keratin 8
CCTCCAGTAC	20	8	2	3	2	4		
CCTGCCCCCC	20	30	6	3	11	4	861	mitogen-activated protein kinase 3
CCTGCTGCAG	7	34	0	1	6	9	102482	mucin 5, subtype B, tracheobronchial
CCTGCTTGTC	20	23	0	3	0	5	268171	ESTs, Weakly similar to
CCTGCTTGTC	20	23	0	3	0	5	2719	epididymis-specific, whey-acidic protein type, four-disulfide core; putative ovarian carcinoma marker
CCTGGAAGAG	30	26	11	4	12	16	75655	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid hormone binding protein p55)
CCTGTCTGCC	14	22	0	1	1	1	107139	hypothetical protein
CCTGTGACAG	22	27	0	4	3	1	120	anti-oxidant protein 2 (non-selenium glutathlone peroxidase, acidic calcium-independent phospholipase A2)
CCTTCAAATC	29	17	0	0	1	0	23118	carbonic anhydrase I
CGAGGGGCCA	110	47	18	18	12	32	182485	actinin, alpha 4
CGCTGTGGGG	58	53	19	8	8	6	7486	protein expressed in thyroid
CGGACTCACT	20	45	5	14	14	10	284134	serologically defined colon cancer antigen 28
CGGACTCACT	20	45	5	14	14	10	84700	similar to phosphatidylcholine transfer protein 2
CGGGAGTCGG	28	30	13	2	9	1	236720	ESTs, Weakly similar to
CGGTGGGACC	7	14	1	1	3	3	99175	Homo sapiens cDNA: FLJ21606 fis, clone COL07302
CGTGGGTGGG	1	10	1	0	0	1	202833	heme oxygenase (decycling) 1
CTACCCTCAC	172	90	30	53	36	58	14376	actin, gamma 1
CTCAGAACTT	18	3	1	0	0	0	194710	glucosaminyl (N-acetyl) transferase 3, mucin type
CTGAACCTCC	5	15	2	0	0	0	4205	hypothetical protein FLJ20124
CTGACCTGTG	88	130	48	18	16	46	77961	major histocompatibility complex, class I, B
CTGGATCTGG	21	21	3	9	5	10	75658	phosphorylase, glycogen; brain
CTGGCAAAGG	14	22	1	0	0	0		
CTGGCCCTCG	186	52	1	3	15	14	1406	trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in)
CTGGCCCTCG	186	52	1	3	15	14	166184	Intersectin 2
CTGGCCCTCG	186	52	1	3	15	14	7720	dynein, cytoplasmic, heavy polypeptide 1

Down - 4

CTGGCTATCC	7	3	0	0	0	1	10784	hypothetical protein FLJ20037
CTGGGCCTCT	22	22	2	2	3	3	50868	solute carrier family 22 (organic cation transporter), member 1-like
CTGTACTTGT	9	5	1	1	0	0	75678	FBJ murine osteosarcoma viral oncogene homolog B
CTGTGTGGCT	0	12	1	0	0	0	127610	acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain
CTGTGTGGCT	0	12	1	0	0	0	54277	DNA segment on chromosome X (unique) 9928 expressed sequence
CTTACAAGCA	21	13	2	3	4	3	mito	Tag matches mitochondrial sequence
CTTAGAGGGG	16	22	0	1	1	1	155191	villin 2 (ezrin)
CTTATGGTCC	36	11	0	1	1	0	179608	retinol dehydrogenase homolog
CTTCCAGCTA	64	31	22	20	14	19	217493	annexin A2
CTTCTTGCCC	29	2	2	2	0	1	251577	hemoglobin, alpha 1
CTTGACATAC	18	20	4	4	0	0	171695	dual specificity phosphatase 1
CTTGATTCCC	26	9	5	0	2	5	77266	quiescin Q6
GACATCAAGT	198	87	23	14	47	17	182265	keratin 19
GACCAGCCCA	23	21	3	2	12	5	75799	protease, serine, 8 (prostasin)
GACCAGTGGC	21	44	4	0	2	0	143131	glycoprotein A33 (transmembrane)
GACGCGGCGC	30	47	10	17	12	17	301684	RNA POLYMERASE I AND TRANSCRIPT RELEASE FACTOR
GAGAGCTCCC	5	11	3	0	2	1	mito	Tag matches mitochondrial sequence
GAGCACCGTG	7	4	1	0	0	1		
GATATGTAAA	1	10	0	0	0	0		
GATCCCAACT	9	29	5	7	1	1	118786	metallothionein 2A
GATGAATCCG	12	14	2	2	1	2	283552	ESTs, Weakly similar to
GATGACCCCC	42	49	4	3	3	3	mito	Tag matches mitochondrial sequence
GCAAGAAAGT	48	0	0	4	0	1	155376	hemoglobin, beta
GCACAGGTCA	5	9	1	0	1	1		
GCACCCTTTC	13	5	0	0	1	0		
GCACCTGTCG	2	9	0	0	1	0	109059	mitochondrial ribosomal protein L12
GCACCTGTCG	2	9	0	0	1	0	1239	alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150)
GCAGCTCCTG	13	47	3	2	7	3	119257	ems1 sequence (mammary tumor and squamous cell carcinoma-associated (p80/85 src substrate)
GCAGGAGGTG	2	13	0	0	0	1	11441	chromosome 1 open reading frame 8
GCAGGAGGTG	2	13	0	0	0	1	76040	KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1

Down-5

GCAGGGCCTC	128	165	41	69	39	51	92323	FXYD domain-containing ion transport regulator 3
GCCACATACT	3	9	0	0	0	0	4984	KIAA0828 protein
GCCACGTGGA	19	16	5	2	7	1	103665	villin-like
GCCAGACACC	19	9	3	4	1	2	3804	DKFZP564C1940 protein
GCCAGGTTGC	14	5	1	1	1	1	42824	hypothetical protein FLJ10718
GCCAGGTTGC	14	5	1	1	1	1	55682	eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67kD)
GCCAGGTTGC	14	5	1	1	1	1	78996	proliferating cell nuclear antigen
GCCATCCTCC	9	13	0	1	0	0		
GCCCACACAG	15	0	1	1	0	0	1690	heparin-binding growth factor binding protein
GCCCACGTCA	7	8	0	0	0	0		
GCCCAGGGCC	4	44	2	1	2	1	10326	coatomer protein complex, subunit epsilon
GCCCAGGGCC	4	44	2	1	2	1	229417	EST, Moderately similar to
GCCCAGGGCC	4	44	2	1	2	1	229546	EST
GCCCAGGTCA	519	447	136	128	58	22	154903	ESTs, Weakly similar to
GCCCAGTGGC	51	0	8	15	2	5	143131	glycoprotein A33 (transmembrane)
GCCGACCAGG	46	47	15	8	19	9	75741	amiloride binding protein 1 (amine oxidase (copper-containing))
GCCGGGTGGG	207	149	18	24	68	67	74631	basigin
GCCGTGGAGA	32	23	4	.11	7	7	80680	major vault protein
GCCTGGCCAT	26	34	4	6	10	14	5662	guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1
GCCTGGCCAT	26	34	4	6	10	14	63042	DKFZp564J157 protein
GCGAAACCCT	167	565	123	43	64	98		
GCGAAACTCG	5	9	1	0	0	0		
GCGCAGAGGT	2	16	1	0	0	1	108124	ribosomal protein L41
GCTCTTCCCC	9	21	1	2	2	0	33455	peptidyl arginine deiminase, type II
GCTGCCCTTG	44	6	13	6	6	18	272897	Tubulin, alpha, brain-specific
GCTGCCCTTG	44	6	13	6	6	18	278242	tubulin, alpha, ubiquitous
GCTGGCACAT	15	14	1	0	6	0	179704	meprin A, alpha (PABA peptide hydrolase)
GCTGGCCCCG	5	11	0	0	0	1	8185	CGI-44 protein; sulfide dehydrogenase like (yeast)
GCTGTGCCTG	36	42	2	4	11	8	58247	protease, serine, 4 (trypsin 4, brain)
GCTTGGGGAT	11	8	2	0	0	0	5394	myosin, heavy polypeptide-like (110kD)
GGAACAGGGG	1	13	1	0	0	2	102336	Rho GTPase activating protein 8
GGAACAGGGG	1	13	1	0	0	2	272972	hypothetical protein FLJ20185
GGAACAGGGG	1	13	1	0	0	2	77961	major histocompatibility complex, class I, B

Down-6

GGAACTGTGA	90	84	10	18	10	2	38972	tetraspan 1
GGAAGAGCAC	21	11	1	1	2	5	75268	sialyltransferase 4C (beta-galactosidase alpha-2,3-sialytransferase)
GGAGGCCGAG	13	9	5	0	2	5	301342	ESTs, Weakly similar to
GGAGGCGCTC	5	11	1	1	0	1	33455	peptidyl arginine deiminase, type II
GGATGGCTTA	25	5	2	1	1	1	64179	hypothetical protein
GGCACCGTGC	22	44	8	10	8	4	120912	ESTs
GGCCCTGCAG	14	7	1	0	5	1	105463	sir2-related protein type 6
GGCTCGGGAT	15	11	2	4	3	5	2575	calpain 1, (mu/I) large subunit
GGCTGCCTGC	13	11	4	3	5	2	180958	ESTs
GGCTGCCTGC	13	11	4	3	5	2	197314	ESTs
GGCTGGGCCT	46	25	14	5	10	8	144102	EST
GGCTGGGCCT	46	25	14	5	10	8	14846	Homo sapiens mRNA; cDNA DKFZp564D016 (from clone DKFZp564D016)
GGCTGGGCCT	46	25	14	5	10	8	73919	clathrin, light polypeptide (Lcb)
GGGAAGCAGA	32	17	18	4	8	9		
GGGACGAGTG	20	6	1	3	6	1	3337	transmembrane 4 superfamily member 1
GGGCGCTGTG	11	27	3	6	4	5	8372	ubiquinol-cytochrome c reductase (6.4kD) subunit
GGGGCAGGGC	48	64	27	10	15	31	119140	eukaryotic translation initiation factor 5A
GGTGAAGAGG	16	32	5	3	10	9	233950	serine protease inhibitor, Kunitz type 1
GTAGCAGGTG	24	27	11	7	7	7	140452	cargo selection protein (mannose 6 phosphate receptor binding protein)
GTATTGGGGC	5	7	0	0	0	0		
GTCATCACCA	35	22	0	0	0	0	107382	KIAA1517 protein
GTCATCACCA	35	22	0	0	0	0	257045	Homo sapiens cDNA: FLJ23415 fis, clone HEP20738
GTCATCACCA	35	22	0	0	0	0	32966	guanylate cyclase activator 2B (uroguanylin)
GTCATCACCA	35	22	0	0	0	0	68877	cytochrome b-245, alpha polypeptide
GTCCGAGTGC	17	3	0	0	0	0	3337	transmembrane 4 superfamily member 1
GTCCTGAACA	7	3	0	0	0	0	78546	ATPase, Ca++ transporting, plasma membrane 1
GTCCTGAACA	7	3	0	0	0	0	8258	DKFZP434D1335 protein
GTGCACTGAG	118	45	14	7	12	13	181244	major histocompatibility complex, class I, A
GTGCACTGAG	118	45	14	7	12	13	277477	major histocompatibility complex, class I, C
GTGCCTGAGA	18	15	2	6	7	3	77886	lamin A/C
GTGGCGGGAA	3	15	1	0	4	0		
GTGGGGGCGC	5	22	2	0	1	0	254105	enolase 1, (alpha)
GTGGTGGCAG	29	11	1	1	10	3	194691	retinoic acid induced 3

Down-7

GTGGTTCACG	4	5	0	0	0	0	272088	ESTs, Moderately similar to
GTGGTTCACG	4	5	0	0	0	0	62192	coagulation factor III (thromboplastin, tissue factor)
GTGTTGGGGG	21	19	8	6	1	3	55016	hypothetical protein FLJ21935
GTTTAGAGGG	5	16	0	0	2	1	181874	interferon-induced protein with tetratricopeptide repeats 4
TAAATTGCAA	103	59	8	17	5	3	56205	Insulin induced gene 1
TAAGGCCTTT	6	9	1	0	0	1	20149	deleted in lymphocytic leukemia, 1
TAAGGCCTTT	6	9	1	0	0	1	42945	acid sphingomyelinase-like phosphodiesterase
TAATCCCAGC	37	33	8	7	16	13		
TAATTTGCAT	25	2	1	1	2	0	79368	epithelial membrane protein 1
TACGGTGTGG	7	13	2	2	1	0	105460	DKFZP564O0823 protein
TACTCGGCCA	10	5	0	0	1	0	79474	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide
TACTGTGGAT	4	11	0	2	2	1	21537	protein phosphatase 1, catalytic subunit, beta isoform
TAGACTAGCA	31	27	6	6	22	4	100090	tetraspan 3
TAGGATGGGG	24	30	4	7	6	1	76941	ATPase, Na+/K+ transporting, beta 3 polypeptide
TATGATGAGC	13	21	2	2	1	5	205126	Homo sapiens cDNA: FLJ22667 fis, clone HSI08385
TCACAGTGCC	26	7	3	1	3	4	81008	filamin B, beta (actin-binding protein-278)
TCACCGGTCA	118	75	10	10	5	6	290070	gelsolin (amyloidosis, Finnish type)
TCAGAGCGCT	5	21	0	7	0	1	92323	FXYD domain-containing ion transport regulator 3
TCAGCTGCAA	56	16	0	0	9	3	284199	mucin 12
TCAGCTGCAA	56	16	0	0	9	3	301888	Homo sapiens cDNA FLJ11205 fis, clone PLACE1007843
TCGGAGCTGT	21	20	9	6	3	0	4055	G protein-coupled receptor kinase-interactor 1
TCTGAATTAT	24	16	0	0	1	0	50964	carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
TGACTAATTG	7	9	2	0	0	3	293380	ESTs
TGAGTGACAG	9	68	0	6	3	7	205126	Homo sapiens cDNA: FLJ22667 fis, clone HSI08385
TGAGTGACAG	9	68	0	6	3	7	271688	ESTs
TGATCTCTGT	6	7	1	0	1	1	30738	hypothetical protein FLJ10407
TGCAGCACGA	6	185	5	30	24	16	110309	major histocompatibility complex, class I, F
TGCAGCGCCT	16	9	1	1	1	1	77573	uridine phosphorylase
TGCCGCCCGC	14	5	2	2	1	0	202097	procollagen C-endopeptidase enhancer
TGCTCCTACC	140	113	70	22	17	22	111732	Fc fragment of IgG binding protein
TGCTCCTACC	140	113	70	22	17	22	301256	Homo sapiens chromosome 19, cosmid R30669

Down-8

TGGCCATCTG	30	24	8	7	3	4	184052	PP1201 protein
TGGCGCGTGT	25	8	0	0	9	5	25640	claudin 3
TGGCTACTTA	6	9	1	0	1	2	117950	multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase
TGGGGAGAGG	43	18	20	7	3	7	288998	S100-type calcium binding protein A14
TTAACCCCTC	34	14	5	9	1	5	78224	ribonuclease, RNase A family, 1 (pancreatic)
TTATGGTGTG	11	17	0	0	0	0	271499	ESTs
TTCCACTAAC	29	9	7	4	5	5	79706	plectin 1, intermediate filament binding protein, 500kD
TTCCGCGTTC	5	16	0	0	2	2	137274	ESTs, Weakly similar to
TTCTGGTGCG	8	2	0	0	1	0	119251	ubiquinol-cytochrome c reductase core protein I
TTCTGTAGCC	13	23	4	2	4	2	5541	ATPase, Ca++ transporting, ubiquitous
TTGGACCTGG	33	31	7	18	12	16	89761	ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit
TTGGGGTTTC	111	184	50	81	67	50	62954	ferritin, heavy polypeptide 1
TTTAACGGCC	93	67	36	35	11	30	mito	Tag matches mitochondrial sequence
TTTCCTCTCA	21	8	6	2	4	3	184510	stratifin
TTTCCTCTCA	21	8	6	2	4	3	303400	ESTs
TTTCTCGTCG	10	16	2	3	0	2	1686	guanine nucleotide binding protein (G protein), alpha 11 (Gq class)
TTTGGTTTCA	2	13	0	0	0	0		
TTTTCTGCAT	8	7	1	0	1	2	50964	carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
TTTTCTGCAT	8	7	1	0	1	2	77318	platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit (45kD)
TTTTTACTGA	32	19	10	10	8	1	111577	integral membrane protein 2C

References

1. Cancer Facts & Figures 1998: American Cancer Society, 1998.
2. Inger, D. B. Colorectal cancer screening, Prim Care. *26:* 179-187, 1999.
3. Velculescu, V. E., Zhang, L., Vogelstein, B., and Kinzler, K. W. Serial Analysis Of Gene Expression, Science. *270:* 484-487, 1995.
4. Zhang, L., Zhou, W., Velculescu, V. E., Kern, S. E., Hruban, R. H., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. Gene Expression Profiles in Normal and Cancer Cells, Science. *276:* 1268-1272, 1997.
5. Lal, A., Lash, A. E., Altschul, S. F., Velculescu, V., Zhang, L., McLendon, R. E., Marra, M. A., Prange, C., Morin, P. J., Polyak, K., Papadopoulos, N., Vogelstein, B., Kinzler, K. W., Strausberg, R. L., and Riggins, G. J. A public database for gene expression in human cancers, Cancer Res. *59:* 5403-5407, 1999.
6. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. Genes expressed in human tumor endothelium, Science. *289:* 1197-1202, 2000.
7. Guy-Crotte, O., Amouric, M., and Figarella, C. Characterization and N-terminal sequence of a degradation product of 14,000 molecular weight isolated from human pancreatic juice, Biochem Biophys Res Commun. *125:* 516-523, 1984.
8. Terazono, K., Yamamoto, H., Takasawa, S., Shiga, K., Yonemura, Y., Tochino, Y., and Okamoto, H. A novel gene activated in regenerating islets, J Biol Chem. *263:* 2111-2114, 1988.
9. Watanabe, T., Yonekura, H., Terazono, K., Yamamoto, H., and Okamoto, H. Complete nucleotide sequence of human reg gene and its expression in normal

and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene, J Biol Chem. *265:* 7432-7439, 1990.

10. Rechreche, H., Montalto, G., Mallo, G. V., Vasseur, S., Marasa, L., Soubeyran, P., Dagorn, J. C., and Iovanna, J. L. pap, reg Ialpha and reg Ibeta mRNAs are concomitantly up-regulated during human colorectal carcinogenesis, Int J Cancer. *81:* 688-694, 1999.

11. Skonier, J., Neubauer, M., Madisen, L., Bennett, K., Plowman, G. D., and Purchio, A. F. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta, DNA Cell Biol. *11:* 511-522, 1992.

12. Escribano, J., Hernando, N., Ghosh, S., Crabb, J., and Coca-Prados, M. cDNA from human ocular ciliary epithelium homologous to beta ig-h3 is preferentially expressed as an extracellular protein in the corneal epithelium, J Cell Physiol. *160:* 511-521, 1994.

13. Munier, F. L., Korvatska, E., Djemai, A., Le Paslier, D., Zografos, L., Pescia, G., and Schorderet, D. F. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies, Nat Genet. *15:* 247-251, 1997.

14. Fleming, A. On a remarkable bacteriolytic element found in tissues and secretions, Proceedings of the Royal Society. *93:* 306-317, 1922.

15. Sugi, K., Saitoh, O., Hirata, I., and Katsu, K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins, Am J Gastroenterol. *91:* 927-934, 1996.

16. van der Sluys Veer, A., Brouwer, J., Biemond, I., Bohbouth, G. E., Verspaget, H. W., and Lamers, C. B. Fecal lysozyme in assessment of disease activity in inflammatory bowel disease, Dig Dis Sci. *43:* 590-595, 1998.

17. Tomita, H., Sato, S., Matsuda, R., Sugiura, Y., Kawaguchi, H., Niimi, T., Yoshida, S., and Morishita, M. Serum lysozyme levels and clinical features of sarcoidosis, Lung. *177:* 161-167, 1999.

18. Ho, S. B., Itzkowitz, S. H., Friera, A. M., Jiang, S. H., and Kim, Y. S. Cell lineage markers in premalignant and malignant colonic mucosa, Gastroenterology. *97:* 392-404, 1989.

19. Yamada, R. and Kera, Y. D-amino acid hydrolysing enzymes, Exs. *85:* 145-155, 1998.

20. Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., Zhang, H. P., Donnellan, M., Mahler, S., Pryor, K., Walsh, B. J., Nicholson, R. C., Fairlie, W. D., Por, S. B., Robbins, J. M., and Breit, S. N. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily, Proc Natl Acad Sci U S A. *94:* 11514-11519, 1997.

21. Paralkar, V. M., Vail, A. L., Grasser, W. A., Brown, T. A., Xu, H., Vukicevic, S., Ke, H. Z., Qi, H., Owen, T. A., and Thompson, D. D. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family, J Biol Chem. *273:* 13760-13767, 1998.

22. Notterman, D.A., Alon, U., Sierk, A.J., Levine, A.J., Transcriptional Gene Expression Profiles of Colorectal Adenoma, Adenocarcinoma, and Normal Tissue Examined by Oligonucleotide Arrays, Cancer Res. *61:* 3124-3130, 2001.

23. Zhou, W., Sokoll, L. J., Brusek, D. J., Zhang, L., Velculsescu, V., Goldin, S. B., Hruban, R. H., Kern, S. E., Hamilton, S. R., Chan, D. W., Vogelstein, B., and

Kinzler, K. W. Identifying markers for pancreatic cancer by gene expression analysis, Can Epid Bio & Prev. *7:* 109-112, 1998.

24. Brown, D. A., Liu, T., Ward, R. L., Hawkins, N. J., Fairlie, W. D., Bauskin, A. R., Russell, P. J., Quinn, D. I., Grygiel, J. J., Moore, A. G., Sutherland, R. L., Turner, J., Kingsley, E. A., and Breit, S. N. Macrophage Inhibitory Cytokine-1 (MIC-1) in epithelial neoplasia, Submitted., 2001.

CLAIMS

1. A method for detection of colorectal cancer, comprising the steps of:
isolating an mRNA sample from feces of a subject;
detecting renal dipeptidase mRNA in said mRNA sample;
comparing the amount of renal dipeptidase mRNA in said mRNA sample to amounts of renal dipeptidase mRNA in normal subjects, wherein an elevated amount of renal dipeptidase mRNA in said mRNA sample is an indicator of colorectal cancer in the subject.

2. The method of claim 1 further comprising the step of:
identifying the patient as having colorectal cancer if an elevated amount of renal dipeptidase mRNA in said mRNA sample is observed.

3. The method of claim 1 wherein renal dipeptidase mRNA is detected by RT-PCR.

4. The method of claim 1 wherein renal dipeptidase mRNA is detected by hybridization of copy mRNA to a nucleic acid array.

5. The method of claim 1 wherein mRNA from one or more genes selected from the group consisting of Tables 3 or 5 is also detected in said mRNA sample and amount of mRNA from said one or more genes is compared to amounts in normal subjects, wherein an elevated amount of at least one of said mRNAs selected from said group and from renal dipeptidase is an indicator of colorectal cancer in the subject.

6. A method for detection of colorectal cancer, comprising the steps of:
isolating epithelial cells from blood of a subject;
isolating an mRNA sample from the epithelial cells;
detecting renal dipeptidase mRNA in said mRNA sample;
comparing the amount of renal dipeptidase mRNA in said mRNA sample to amounts of renal dipeptidase mRNA in normal subjects, wherein an elevated

amount of renal dipeptidase mRNA in said mRNA sample is an indicator of colorectal cancer in the subject.

7. The method of claim 6 further comprising the step of:
identifying the patient as having colorectal cancer if an elevated amount of renal dipeptidase mRNA in said mRNA sample is observed.

8. The method of claim 6 wherein renal dipeptidase mRNA is detected by RT-PCR.

9. The method of claim 6 wherein renal dipeptidase mRNA is detected by hybridization of copy mRNA to a nucleic acid array.

10. The method of claim 6 wherein mRNA from one or more genes selected from the group consisting of Tables 3 and 5 is also detected in said mRNA sample and amount of mRNA from said one or more genes is compared to amounts in normal subjects, wherein an elevated amount of at least one of said mRNAs selected from said group and from renal dipeptidase is an indicator of colorectal cancer in the subject.

11. A method for detection of colorectal cancer, comprising the steps of:
contacting blood of a subject with an renal dipeptidase substrate;
detecting activity of renal dipeptidase in said blood by detection of increased reaction product or decreased renal dipeptidase substrate;
comparing the amount of activity of renal dipeptidase in blood of the subject to that in normal subjects, wherein an elevated amount of activity of renal dipeptidase in the blood of the subject is an indicator of colorectal cancer in the subject.

12. The method of claim 11 wherein the renal dipeptidase substrate is labeled with a fluor.

13. The method of claim 11 wherein the renal dipeptidase substrate is labeled with a radioactive atom.

14. The method of claim 11 wherein the renal dipeptidase substrate comprises a C-terminal D –amino acid.

15. A method for detection of colorectal cancer, comprising the steps of:
contacting feces of a subject with a renal dipeptidase substrate;

detecting activity of renal dipeptidase in said feces by detection of increased reaction product or decreased renal dipeptidase substrate;

comparing the amount of activity of renal dipeptidase in feces of the subject to that in normal subjects, wherein an elevated amount of activity of renal dipeptidase in the feces of the subject is an indicator of colorectal cancer in the subject.

16. The method of claim 16 wherein the renal dipeptidase substrate is labeled with a fluor.
17. The method of claim 16 wherein the renal dipeptidase substrate is labeled with a radioactive atom.
18. The method of claim 16 wherein the renal dipeptidase substrate comprises a C-terminal D –amino acid.
19. A method for detection of colorectal cancer, comprising the steps of:

    administering to a subject an antibody which specifically binds to renal dipeptidase wherein the antibody is labeled with a moiety which is detectable from outside of the subject;

    detecting the moiety in the subject from outside of the subject, wherein an area of localization of the moiety within the subject but outside the proximal tubules of the kidney identifies colorectal cancer.
20. The method of claim 19 wherein the moiety is a fluor.
21. The method of claim 19 wherein the moiety is a radioactive atom.
22. The method of claim 19 wherein the moiety is a contrast agent for spiral computer tomography.
23. A method for detection of colorectal cancer, comprising the steps of:

administering to a subject an inhibitor of renal dipeptidase wherein the inhibitor is labeled with a moiety which is detectable from outside of the subject;

detecting the moiety in the subject from outside of the subject, wherein an area of localization of the moiety within the subject but outside the proximal tubules of the kidney identifies colorectal cancer.

24. The method of claim 23 wherein the moiety is a fluor.
25. The method of claim 23 wherein the moiety is a radioactive atom.
26. The method of claim 23 wherein the moiety is a contrast agent for spiral computer tomography

27. The method of claim 23 wherein the inhibitor binds irreversibly to renal dipeptidase.

28. The method of claim 23 wherein the inhibitor binds and slowly releases from renal dipeptidase with a half-life of greater than 4 hours.

29. A method for detection of colorectal cancer, comprising the steps of:

administering to a subject a substrate for renal dipeptidase, said substrate being labeled with a detectable moiety;

isolating feces from the subject;

detecting in the feces renal dipeptidase reaction product or renal dipeptidase substrate with the detectable moiety, wherein increased product or decreased substrate in the feces indicates colorectal cancer in the subject.

30. The method of claim 29 wherein the substrate is administered orally.

31. The method of claim 29 wherein the substrate is administered intravenously.

32. The method of claim 29 wherein the substrate is administered rectally.

33. A method for detection of colorectal cancer, comprising the steps of:

administering to a subject a substrate for renal dipeptidase, said substrate being labeled with a detectable moiety;

isolating blood from the subject;

detecting in the blood renal dipeptidase reaction product or renal dipeptidase substrate with the detecable moiety, wherein increased product or decreased substrate in the blood indicates colorectal cancer in the subject.

34. The method of claim 33 wherein the substrate is administered orally.

35. The method of claim 33 wherein the substrate is administered intravenously.

36. The method of claim 33 wherein the substrate is administered rectally.

37. A method for detection of colorectal cancer, comprising the steps of:

isolating an mRNA sample from feces of a subject;

detecting macrophage inhibitory cytokine mRNA in said mRNA sample;

comparing the amount of macrophage inhibitory cytokine mRNA in said mRNA sample to amounts of macrophage inhibitory cytokine mRNA in normal

subjects, wherein an elevated amount of macrophage inhibitory cytokine mRNA in said mRNA sample is an indicator of colorectal cancer in the subject.

38. The method of claim 37 further comprising the step of:
identifying the patient as having colorectal cancer if an elevated amount of macrophage inhibitory cytokine mRNA in said mRNA sample is observed.

39. The method of claim 37 wherein macrophage inhibitory cytokine mRNA is detected by RT-PCR.

40. The method of claim 37 wherein macrophage inhibitory cytokine mRNA is detected by hybridization of copy mRNA to a nucleic acid array.

41. The method of claim 37 wherein mRNA from one or more genes selected from the group consisting of Tables 3 and 5 is also detected in said mRNA sample and amount of mRNA from said one or more genes is compared to amounts in normal subjects, wherein an elevated amount of at least one of said mRNAs selected from said group and from macrophage inhibitory cytokine is an indicator of colorectal cancer in the subject.

42. A method for detection of colorectal cancer, comprising the steps of:
isolating epithelial cells from blood of a subject;
isolating an mRNA sample from the epithelial cells;
detecting macrophage inhibitory cytokine mRNA in said mRNA sample;
comparing the amount of macrophage inhibitory cytokine mRNA in said mRNA sample to amounts of macrophage inhibitory cytokine mRNA in normal subjects, wherein an elevated amount of macrophage inhibitory cytokine mRNA in said mRNA sample is an indicator of colorectal cancer in the subject.

43. The method of claim 42 further comprising the step of:
identifying the patient as having colorectal cancer if an elevated amount of macrophage inhibitory cytokine mRNA in said mRNA sample is observed.

44. The method of claim 42 wherein macrophage inhibitory cytokine mRNA is detected by RT-PCR.

45. The method of claim 42 wherein macrophage inhibitory cytokine mRNA is detected by hybridization of copy mRNA to a nucleic acid array.

46. The method of claim 42 wherein mRNA from one or more genes selected from the group consisting of Tables 3 and 5 is also detected in said mRNA sample and amount of mRNA from said one or more genes is compared to amounts in normal subjects, wherein an elevated amount of at least one of said mRNAs selected from said group and from macrophage inhibitory cytokine is an indicator of colorectal cancer in the subject.

47. A method for detection of colorectal cancer, comprising the steps of:
detecting macrophage inhibitory cytokine in blood of a subject and
comparing the amount of macrophage inhibitory cytokine in blood of the subject to that in normal subjects, wherein an elevated amount of macrophage inhibitory cytokine in the blood of the subject is an indicator of colorectal cancer in the subject.

48. A method for detection of colorectal cancer, comprising the steps of:
detecting macrophage inhibitory cytokine in feces of a subject; and
comparing the amount of macrophage inhibitory cytokine in feces of the subject to that in normal subjects, wherein an elevated amount of macrophage inhibitory cytokine in the feces of the subject is an indicator of colorectal cancer in the subject.

49. A method for detection of colorectal cancer, comprising the steps of:
detecting renal dipeptidase in blood of a subject; and
comparing amount of renal dipeptidase in blood of the subject to the amount of renal dipeptidase in normal subjects, wherein an elevated amount of renal dipeptidase in the blood of the subject is an indicator of colorectal cancer in the subject.

50. A method for detection of colorectal cancer, comprising the steps of:
detecting renal dipeptidase in feces of a subject; and
comparing amount of renal dipeptidase in feces of the subject to the amount of renal dipeptidase in normal subjects, wherein an elevated amount of

renal dipeptidase in the feces of the subject is an indicator of colorectal cancer in the subject.

FIG. 1A



FIG. 1B



FIG. 2





FIG. 3


FIG. 4
Fold Elevation
200
150
100
15
10
5
0
N-1
Ca-1
N-2
Ca-2
TGFBI
LYS
RDP
MIC-1
REGA
DEHL



FIG. 5A

FIG. 5B



FIG. 5C



FIG. 5D



FIG. 5E

FIG.6



G-89 ≡ 10 nM



G-90 ≡ 17.6 nM



G-132 ≡ 0.8nM
*(RACEMATE)



G-133 ≡ 0.6nM
*(PURE STEREOISOMER)
(L?)



G-136 ≡ 2.3nM
*(RACEMATE)



G-110 ≡ 1.2nM



G-111 ≡ 19.5nM


FIG. 7
Compare Inhibs
Vi/Vo
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.01
0.1
1
10
100
1000
10000
100000
[Inhib] (nM)
G89
G90
G110
G111
G132
G133
G136
G000

FIG. 8

Renal Dipeptidase Substrates





FIG. 9

Renal Dipeptidase Enzyme Activity in Human Tumors







INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/28518

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04
US CL : 435/6, 91.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/6, 91.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	BUCKHAULTS et al. Secreted and Cell Surface Genes Expressed in Benign and Malignant Colorectal Tumors. Cancer Research. 01 October 2001, Vol. 61, pages	1-10
X, P	US 6,333, 152 B1 (VOGELSTEIN et al.) 25 December 2001 (25.12.2001), columns 16-17, sequence 50	1-10
A	ISHIGAMI et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. British Journal of Cancer. 1998, Vol. 78, No. 10, pages 1379-1384.	1-10
A	OTTE et al. Expression of keratinocyte growth factor and its receptor in colorectal cancer. European Journal of Clinical Investigation. 2000, Vol. 30, pages 222-229.	1-10

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
09 December 2002 (09.12.2002)

Date of mailing of the international search report
31 JAN 2003

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703)305-3230

Authorized officer
Juliet C. Einsmann
Janice Ford for
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/28518

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: Claims 1-10, species Lysosyme

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US02/28518

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

Group 1, claims 1-10, drawn to methods for detecting colorectal cancer wherein renal dipeptidase mRNA is detected.

Group 2, claims 11-18, drawn to methods for detecting colorectal cancer which target the peptide renal dipeptidase in a detection assay.

Group 3, claims 19-22, drawn to methods for detection of colorectal cancer wherein an antibody is administered to a patient.

Group 4, claims 23-28, drawn to methods for detection of colorectal cancer wherein an inhibitor is administered to a subject.

Group 5, claims 29-36, drawn to methods for detection of colorectal cancer wherein a substrate for renal dipeptidase is administered to a patient.

Group 6, claims 37-46, drawn to a method for the detection of colorectal cancer wherein macrophage inhibitory cytokine mRNA is detected.

Group 7, claims 47-50, drawn to methods for detecting colorectal cancer which target the macrophage inhibitory cytokine in a detection assay.

Further species election for groups 1 and 6. These groups further recite dependent claims wherein one of a multitude of sequences selected from table 3 or table 5 are utilized in the assay. Each of these is a separate species, and if applicant wishes for more than one to be examined in the claims, appropriate fees must be paid.

The invention which is the first invention to be searched is group 1, claims 1-10, with respect to the recited sequence in table 3.

The inventions listed as groups 1-7 do not relate to a single general concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features because each of the recited groups is drawn to a method which has a unique feature that is not shared with the other groups. The special technical feature of group 1 is considered to be a method in which renal dipeptidase mRNA is detected as an indicator of colorectal cancer, while in group 2 has a special technical feature wherein peptide renal dipeptidase is detected. The special technical feature of group 3 is that an antibody is administered to a patient for the detection of colorectal cancer. The special technical feature of group 4 is that an inhibitor is administered to a patient for the detection of colorectal cancer. The special technical feature of group 5 is that a substrate for renal dipeptidase is administered to a patient for the detection of colorectal cancer. Groups 6 and 7 are not joined to groups 1-4 because they employ macorphage inhibitory cytokine as a target for the detection of colorectal cancer. . The special technical feature of group 6 is considered to be a method in which macrophage inhibitory cytokine mRNA is detected as an indicator of colorectal cancer, while in group 7 has a special technical feature wherein macrophage inhibitory cytokine is detected.

Further, the separate species recited in table 3 and table 5 are not joined to one another because they are each distinct nucleic acids with separate structures and functions.

Continuation of B. FIELDS SEARCHED Item 3:
USPATS, MEDLINE, BIOSIS, CAPLUS
keywords: renal dipeptidase (and synonyms), colorectal, colon, rectum, cancer, carcinoma, tumor

patsnap

专利名称(译)	分泌的和细胞表面基因在良性和恶性结肠直肠肿瘤中表达		
公开(公告)号	EP1430071A1	公开(公告)日	2004-06-23
申请号	EP2002773302	申请日	2002-09-09
[标]申请(专利权)人(译)	医学的约翰霍普金斯大学医学院		
申请(专利权)人(译)	医学的约翰霍普金斯大学医学院		
当前申请(专利权)人(译)	医学的约翰霍普金斯大学医学院		
[标]发明人	BUCKHAULTS PHILLIP KINZLER KENNETH W VOGELSTEIN BERT		
发明人	BUCKHAULTS, PHILLIP KINZLER, KENNETH, W. VOGELSTEIN, BERT		
IPC分类号	G01N33/53 A61K49/00 A61K51/00 C07K14/47 C07K14/495 C07K14/705 C12N9/48 C12N15/09 C12Q1/37 C12Q1/68 G01N21/78 G01N37/00 C07H21/04		
CPC分类号	C07K14/495 C07K14/47 C07K14/705		
代理机构(译)	汤布林，ADRIAN GEORGE		
优先权	60/317494 2001-09-07 US 60/383805 2002-05-30 US		
其他公开文献	EP1430071A4 EP1430071B1		
外部链接	Espacenet		

摘要(译)

基因表达的系列分析（SAGE）用于鉴定编码在结肠直肠的良性和恶性肿瘤中表达的分泌或细胞表面蛋白的转录物。从正常，腺瘤和癌性结肠上皮分析总共290,394个标签。在观察到的21,343种不同转录物中，发现957种在正常和腺瘤之间或在正常和癌症之间差异表达。 49个转录物在腺瘤中升高≥20倍，40个转录物在癌症中升高≥20倍，并且9个转录物在两者中升高≥20倍。预测六种这九种转录物（TGFBI，LYS，RDP，MIC-1，REGA和DEHL）的产物被分泌或驻留在细胞表面上，并且更详细地分析这些。通过对这六种基因中的每一种进行定量PCR分析来确认SAGE预测的异常表达水平。此外，通过原位杂交和通过PCR分析从原发性肿瘤纯化的上皮细胞免疫亲和来鉴定负责表达升高的细胞类型。